



Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy

Sheila M. Hegde, MD,^a Steven J. Lester, MD,^b Scott D. Solomon, MD,^a Michelle Michels, MD,^c Perry M. Elliott, MD,^d Sherif F. Nagueh, MD,^e Lubna Choudhury, MD,^f David Zemanek, MD,^g Donna R. Zwas, MD, MPH,^h Daniel Jacoby, MD,ⁱ Andrew Wang, MD,^j Carolyn Y. Ho, MD,^a Wanying Li, PhD,^k Amy J. Sehnert, MD,^k Iacopo Olivetto, MD,^l Theodore P. Abraham, MD^m

ABSTRACT

BACKGROUND EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) demonstrated that mavacamten, a cardiac myosin inhibitor, improves symptoms, exercise capacity, and left ventricular outflow tract (LVOT) obstruction in patients with obstructive hypertrophic cardiomyopathy (oHCM).

OBJECTIVES The purpose of this study was to evaluate mavacamten's effect on measures of cardiac structure and function and its association with changes in other clinical measures.

METHODS Key echocardiographic parameters from serial echocardiograms over 30 weeks from 251 symptomatic oHCM patients (mavacamten [n = 123], placebo [n = 128]) were assessed in a core laboratory.

RESULTS More patients on mavacamten (80.9%; n = 76 of 94) vs placebo (34.0%; n = 33 of 97) showed complete resolution of mitral valve systolic anterior motion after 30 weeks (difference, 46.8%; $P < 0.0001$). Mavacamten also improved measures of diastolic function vs placebo, including left atrial volume index (LAVI) (mean \pm SD baseline: 40 ± 12 mL/m² vs 41 ± 14 mL/m²; mean change from baseline of -7.5 mL/m² [95% CI: -9.0 to -6.1 mL/m²] vs -0.09 mL/m² [95% CI: -1.6 to 1.5 mL/m²]; $P < 0.0001$) and lateral E/e' (baseline, 15 ± 6 vs 15 ± 8 ; change of -3.8 [95% CI: -4.7 to -2.8] vs 0.04 [95% CI: -0.9 to 1.0]; $P < 0.0001$). Among mavacamten-treated patients, improvement in resting, Valsalva, and post-exercise LVOT gradients, LAVI, and lateral E/e' was associated with reduction in N-terminal pro-B-type natriuretic peptide ($P \leq 0.03$ for all). Reduction in LAVI was associated with improved peak exercise oxygen consumption ($P = 0.04$).

CONCLUSIONS Mavacamten significantly improved measures of left ventricular diastolic function and systolic anterior motion. Improvement in LVOT obstruction, LAVI, and E/e' was associated with reduction in a biomarker of myocardial wall stress (N-terminal pro-B-type natriuretic peptide). These findings demonstrate improvement in important markers of the pathophysiology of oHCM with mavacamten. (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; [NCT03470545](https://clinicaltrials.gov/ct2/show/study/NCT03470545)) (J Am Coll Cardiol 2021;78:2518-2532)
© 2021 by the American College of Cardiology Foundation.



Listen to this manuscript's audio summary by Editor-in-Chief Dr Valentin Fuster on JACC.org.

From the ^aDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; ^bDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA; ^cDepartment of Cardiology, Thoraxcenter, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands; ^dInstitute of Cardiovascular Science, University College London, London, United Kingdom; ^eMethodist DeBakey Heart and Vascular Center, Houston, Texas, USA; ^fBluhm Cardiovascular Institute, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA; ^g2nd Department of Internal Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; ^hHeart Institute, Hadassah University Medical Center, Jerusalem, Israel; ⁱDepartment of Internal Medicine, Section of Cardiovascular Medicine, Yale University, New Haven, Connecticut, USA; ^jDuke University School of Medicine, Durham, North Carolina, USA; ^kMyoKardia, Inc, a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, California, USA; ^lCardiomyopathy Unit, Azienda Ospedaliera Universitaria Careggi and the University of Florence, Florence, Italy; and the ^mUCSF HCM Center of Excellence, University of California San Francisco, San Francisco, California, USA.

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder characterized by left ventricular (LV) hypertrophy, hyperdynamic contraction, and impaired relaxation leading to progressive symptoms (1,2). Many patients develop dynamic left ventricular outflow tract (LVOT) obstruction (obstructive HCM), an important prognostic factor in these patients that is associated with an increased risk of disease progression, including heart failure, atrial fibrillation, and death (3,4). Echocardiography is essential to the diagnosis and monitoring of HCM (2,5). It is routinely used to assess structural and functional cardiac abnormalities, including LVOT gradient, degree of hypertrophy, systolic and diastolic function, as well as the response to therapy in this patient population. Current guidelines for the pharmacological management of HCM recommend the use of negative inotropic agents, including β -blockers, nondihydropyridine calcium-channel blockers, and disopyramide for symptom relief; however, these recommendations are based on non-randomized studies and limited data (2,5). Furthermore, no available agent has been shown to improve the natural history of the disease or to convincingly improve diastolic function in HCM, and none target the underlying pathophysiology of the disease (6,7).

SEE PAGE 2533

Mavacamten, a novel, small molecule inhibitor of cardiac myosin, reduces excess actin-myosin cross-bridging by decreasing myosin adenosine triphosphatase activity of the cardiac myosin heavy chain, which results in decreased sarcomere power and force generation, or decreased contractility (8-10). Preclinical data have shown that mavacamten reduced contractility, resolved mitral valve systolic anterior motion (SAM), and reduced LVOT gradients, and if given earlier in life, there was attenuation of LV hypertrophy, cardiomyocyte disarray, and myocardial fibrosis (9,10). A phase 2 nonrandomized clinical study demonstrated symptom improvement and LVOT gradient reduction in 21 symptomatic obstructive HCM patients treated with mavacamten (11). These findings were confirmed in the randomized, double-blind, placebo-controlled, phase 3 EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461]

in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy), which demonstrated significant reduction in LVOT gradients, improved exercise capacity, improved health status, and decreased symptom burden without clinically significant changes in LV ejection fraction after 30 weeks of mavacamten treatment (12,13). Significant reductions in LV mass index, absolute intracellular myocardial mass index, maximum LV wall thickness, and left atrial volume index (LAVI) with mavacamten were demonstrated in a cardiac magnetic resonance imaging substudy of 35 EXPLORER-HCM subjects (14).

The objective of this secondary analysis of EXPLORER-HCM was to evaluate the effect of mavacamten on key echocardiographic features of obstructive HCM and how these changes relate to its observed benefits in cardiac biomarkers and exercise capacity.

METHODS

STUDY DESIGN AND PATIENT POPULATION. EXPLORER-HCM (NCT03470545) was a multicenter, double-blind, placebo-controlled, randomized, phase 3 study in patients with symptomatic obstructive HCM. Details of the study design and primary efficacy and safety results have been published previously (12,15). As described, eligible patients were at least 18 years of age with obstructive HCM with unexplained LV hypertrophy; peak LVOT gradient ≥ 50 mm Hg at rest, with Valsalva maneuver, or during exercise; LV ejection fraction $\geq 55\%$; and New York Heart Association functional class II-III symptoms. Subjects were allowed to continue standard medical therapy except for disopyramide. The protocol was approved by institutional review boards at all sites, and all patients provided informed consent.

PROCEDURES AND ASSESSMENTS. Resting echocardiograms were performed at screening; day 1; and weeks 4, 6, 12, 18, 22, 26, 30 (end of treatment), and 38 (end of study). Postexercise echocardiograms were performed at screening and week 30. All echocardiograms were acquired according to a detailed acquisition protocol by certified sonographers at each site.

ABBREVIATIONS AND ACRONYMS

- e'** = early diastolic mitral annular velocity
- E/e'** = ratio between early mitral inflow velocity and mitral annular early diastolic velocity
- HCM** = hypertrophic cardiomyopathy
- LA** = left atrium/atrial
- LAVI** = left atrial volume index
- LV** = left ventricle/ventricular
- LVMI** = left ventricular mass index
- LVOT** = left ventricular outflow tract
- NT-proBNP** = N-terminal pro-B-type natriuretic peptide
- SAM** = systolic anterior motion

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Manuscript received July 9, 2021; revised manuscript received August 27, 2021, accepted September 28, 2021.

TABLE 1 Baseline Demographics and Characteristics

	Mavacamten (n = 123)	Placebo (n = 128)
Demographics		
Age, y	58.5 ± 12.2	58.5 ± 11.8
Female	57 (46)	45 (35)
HCM-related characteristics		
Hypertension	57 (46)	53 (41)
Atrial fibrillation	12 (10)	23 (18)
Septal reduction therapy	11 (9)	8 (6)
Myectomy	1 (1)	2 (2)
Alcohol septal ablation	10 (8)	6 (5)
Family history of HCM ^a	33 (27)	36 (28)
% pathogenic or likely pathogenic HCM gene variant ^b	28/90 (31)	22/100 (22)
Type 2 diabetes	6 (5)	7 (6)
Body mass index, kg/m ²	29.7 ± 4.9	29.2 ± 5.6
Heart rate, beats/min	63 ± 10.1	62 ± 10.6
Systolic blood pressure, mm Hg	128 ± 16.2	128 ± 14.6
Diastolic blood pressure, mm Hg	75 ± 10.8	76 ± 9.9
NYHA functional class		
II	88 (72)	95 (74)
III	35 (29)	33 (26)
Baseline pharmacotherapy		
β-blocker	94 (76)	95 (74)
Calcium-channel blocker	25 (20)	17 (13)
ACE inhibitor/ARB	20 (16)	26 (20)
Mineralocorticoid receptor antagonists	7 (6)	9 (7)
Diuretic agents	22 (18)	22 (17)
NT-proBNP, geometric mean, ng/L (CV%) ^c	777 (136) (n = 120)	616 (108) (n = 126)
hs-cTnI, geometric mean, ng/L (CV%) ^c	12.5 (208) (n = 120)	12.5 (373) (n = 119)
Echocardiographic parameters		
LVEF, %	74 ± 6	74 ± 6
LVOT gradient, mm Hg		
Resting	52 ± 29	51 ± 32
Valsalva	72 ± 32	74 ± 32
Postexercise	86 ± 34 (122)	84 ± 36 (127)
LV end-diastolic dimension, mm	40 ± 5 (117)	41 ± 5 (124)
LV end-systolic dimension, mm	23 ± 3 (96)	24 ± 4 (104)
Interventricular septal thickness, mm	17 ± 3 (121)	17 ± 3 (127)
Inferolateral wall thickness, mm	12 ± 2 (118)	11 ± 2 (124)
Max LV wall thickness, mm	20 ± 4	20 ± 3
LVMI, g/m ²	112 ± 27 (117)	110 ± 26 (123)
LAVI, mL/m ²	40 ± 12 (122)	41 ± 14 (128)
Lateral e', cm/s	6 ± 2 (118)	7 ± 2 (126)
Septal e', cm/s	5 ± 1 (123)	5 ± 2 (127)
E/e' lateral ratio	15 ± 6 (118)	15 ± 8 (122)
E/e' septal ratio	20 ± 7 (123)	20 ± 9 (127)
Peak E-wave velocity, cm/s	88 ± 25 (123)	89 ± 28 (128)
Peak A-wave velocity, cm/s	80 ± 26 (121)	79 ± 26 (123)
SAM	97/119 (82)	102/126 (81)
Mitral regurgitation	117/120 (98)	124/125 (99)
RVSP, mm Hg	29 ± 8 (43)	27 ± 8 (42)

Values are mean ± SD, n (%), mean ± SD (n), or n/N (%). ^aFamily history of HCM was self-reported. ^bDenominator indicates number of subjects with gene testing performed. ^cLog-normally distributed values are summarized as geometric mean (CV%).

ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; CV = coefficient of variation; e' = early diastolic mitral annular velocity; E/e' = ratio between early mitral inflow velocity and mitral annular early diastolic velocity; HCM = hypertrophic cardiomyopathy; hs-cTnI = high-sensitivity cardiac troponin I; LAVI = left atrial volume index; LV = left ventricular; LVEF = left ventricular ejection fraction; LVMI = left ventricular mass index; LVOT = left ventricular outflow tract; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association; RVSP = right ventricular systolic pressure; SAM = systolic anterior motion.

Images were assessed by the Cardiovascular Imaging Core Laboratory (Brigham and Women's Hospital) according to American Society of Echocardiography recommendations (16). Core laboratory personnel performing the measurements were blinded to study treatment. Chamber dimensions included LV end-systolic and end-diastolic dimensions, LAVI, maximum LV wall thickness, interventricular septal wall thickness, and inferolateral wall thickness. LV ejection fraction was based on the modified Simpson's method. Maximum LV wall thickness at baseline was measured as the greatest wall thickness visualized in the parasternal long- and short-axis views. Left ventricular mass index (LVMI) was calculated from linear dimensions and indexed to height^{2.7} per guidelines, although we acknowledge that accurate assessment of LVMI using echocardiography is limited by the atypical morphology seen in obstructive HCM (16). Markers related to ventricular filling included lateral and septal early diastolic mitral annular velocity (lateral e' and septal e', respectively), ratio between early mitral inflow velocity and lateral mitral annular early diastolic velocity (lateral E/e'), and ratio between early mitral inflow velocity and septal mitral annular early diastolic velocity (septal E/e'). LVOT gradient assessments included instantaneous peak LVOT gradient at rest, provoked peak LVOT gradient with the Valsalva maneuver, and instantaneous peak LVOT gradient immediately following exercise. Sonographers were instructed to sweep the angle of interrogation from the left atrium to the LVOT to aid the ability to distinguish between mitral regurgitation and LVOT Doppler profiles. The presence of mitral valve SAM and mitral regurgitation was assessed as either present or absent. Complete resolution of SAM was defined as those who were identified with SAM present at baseline and absent at week 30. LVOT gradients and LV ejection fraction at rest were assessed at each study visit to allow for drug titration, whereas a more thorough echocardiographic assessment was performed at baseline, week 18, and week 30.

STATISTICAL ANALYSES. In this exploratory analysis, baseline values of the echocardiographic parameters, the last nonmissing measurements before the first dose of the study drug, were summarized using descriptive statistics. For the analysis comparing the changes from baseline in continuous echocardiographic measurements (eg, LAVI, e', and E/e') between treatment arms, least-squares means, 95% CIs, and P values were calculated using a mixed model for repeated measurements for data up to week 30, with treatment group (mavacamten vs placebo), time points, the interaction between treatment

and time point, corresponding baseline value, and stratification factors (β -blocker use, New York Heart Association functional class, and ergometer type) as fixed effects and patient as random effect. The categorical variables (absence of SAM or mitral regurgitation) were analyzed using the Cochran-Mantel-Haenszel test stratified by New York Heart Association functional class, β -blocker use, and ergometer type.

Additional exploratory, post hoc analyses were conducted to assess the relationship between the baseline LVOT Valsalva gradients and mavacamten treatment effect on echocardiographic parameters (LAVI, e' , and E/e'). The linear model was fitted on the change in echocardiographic parameter of interest with its baseline value, baseline LVOT Valsalva gradient, treatment, interaction between treatment, and those 2 baseline variables as explanatory variables.

The relationship between the changes from baseline to week 30 in echocardiographic parameters, LVOT gradients, and other clinical parameters was explored under the effect of mavacamten treatment. Simple linear regression was fitted by treatment group on the change in log₂ transformed cardiac biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP] and high-sensitivity cardiac troponin I) and change in peak oxygen consumption (pVO_2), separately, with the change in each individual echocardiographic parameter (LVOT gradient, LAVI, E/e' , e') as the explanatory variable. The fitted lines were overlaid with scatter plots. Note, the cardiac biomarker data were analyzed on a log₂ scale as the biomarker data showed a log-normal-like distribution.

Missing data were not imputed. P values <0.05 were considered statistically significant. P values and 95% CIs presented in this report have not been adjusted for multiplicity because of the exploratory nature of the analyses. SAS version 9.4 or higher (SAS Institute) was used for all statistical analyses.

RESULTS

Of the 251 patients with symptomatic obstructive HCM enrolled in EXPLORER-HCM, 123 (49%) received mavacamten and 128 (51%) received placebo. Baseline demographics have been described previously (12). The mean age was 58.5 years, 41% of patients were women, and 92% were on background β -blocker or calcium-channel blocker therapy. In total, 9 subjects (7 mavacamten, 2 placebo) experienced a decline in LV ejection fraction (median 48% [range 35%-49%]), 7 subjects (4 mavacamten, 3 placebo) discontinued


treatment, and no subjects were lost to follow-up in the first 30 weeks (Supplemental Tables 1 and 2). In those who experienced an LV ejection fraction decline, LV function recovered with protocol-driven temporary treatment discontinuation; all subjects resumed mavacamten dosing at the same or lower dose per protocol and completed the study.

Baseline echocardiography demonstrated typical features of HCM with increased maximum LV wall thickness, reduced tissue Doppler indexes of mitral annular e' velocities, elevated E/e' , and mild left atrial (LA) enlargement (Table 1). Patients had elevated LVOT gradients (rest, Valsalva, and post-exercise), consistent with the study entry criteria.

PHYSIOLOGICAL CHANGES. For patients with mitral valve SAM at baseline, treatment with mavacamten for 30 weeks led to complete resolution of SAM in 80.9% of patients ($n = 76$ of 94) compared with 34.0% of patients receiving placebo ($n = 33$ of 97), a difference of 46.8% (95% CI: 34.5% to 59.2%; $P < 0.0001$). For patients with mitral regurgitation at baseline, 9.0% ($n = 10$ of 111) of patients in the mavacamten group had complete resolution of mitral regurgitation compared with no patients in the placebo group (difference of 9.0% [95% CI: 3.7% to 14.3%]; $P < 0.001$). LV ejection fraction decreased compared with placebo (mean baseline of $74\% \pm 6\%$ vs $74\% \pm 6\%$; mean change from baseline of -3.9% [95% CI: -5.3% to -2.5%] vs -0.01% [95% CI: -1.2% to 1.2%]; $P < 0.0001$) (12).


Patients treated with mavacamten also had significant improvement in markers of LV diastolic function compared with placebo (Figures 1 and 2, Table 2). The mean decrease from baseline in LAVI at week 30 was -7.5 mL/m² (95% CI: -9.0 to -6.1 mL/m²) with mavacamten vs -0.1 mL/m² (95% CI: -1.6 to 1.5 mL/m²) with placebo ($P < 0.0001$). Mavacamten was also associated with improvement in septal e' (mean increase of 0.7 cm/s [95% CI: 0.4 to 1.0 cm/s] vs -0.02 cm/s [95% CI: -0.2 to 0.2 cm/s]; $P < 0.0001$), lateral e' (mean increase of 1.6 cm/s [95% CI: 1.2 to 1.9 cm/s] vs 0.2 cm/s [95% CI: -0.2 to 0.5 cm/s]; $P < 0.0001$), septal E/e' (mean decrease of -3.5 [95% CI: -4.7 to -2.4] vs -0.3 [95% CI: -1.1 to 0.6]; $P < 0.0001$), and lateral E/e' (mean decrease of -3.8 [95% CI: -4.7 to -2.8] vs 0.04 [95% CI: -0.9 to 1.0]; $P < 0.0001$). Significant improvements were detectable as early as week 18 in LAVI, septal e' , lateral e' , septal E/e' , and lateral E/e' and persisted through week 30 (Figure 1). No significant changes were seen in mitral inflow E and A velocities. Reduction in LVOT gradients (rest, Valsalva), LAVI, and E/e' were similar in subjects treated with mavacamten with and without

FIGURE 1 Echocardiographic Parameters Over Time




Number of Patients at Visit

—●— Mavacamten	122	116	116
—●— Placebo	128	118	123



Number of Patients at Visit

—●— Mavacamten	121	116	116
—●— Placebo	127	121	121




Number of Patients at Visit

—●— Mavacamten	118	113	113
—●— Placebo	124	117	115


Continued on the next page

FIGURE 1 Continued




Number of Patients at Visit

— Mavacamten	123	112	113
— Placebo	127	118	120



Number of Patients at Visit


— Mavacamten	118	110	111
— Placebo	126	113	118



Number of Patients at Visit

— Mavacamten	123	112	111
— Placebo	127	116	118

Continued on the next page




complete resolution of mitral valve SAM (Supplemental Table 3).

STRUCTURAL CHANGES. The LV end-diastolic dimension did not significantly change after 30 weeks with mavacamten compared with placebo (mean ± SD baseline of 40 ± 5 mm vs 41 ± 5 mm; mean decrease from baseline of -1.0 mm [95% CI: -1.5 to -0.4 mm] vs -0.3 mm [95% CI: -0.9 to

0.3 mm]; *P* = 0.05), whereas the LV end-systolic dimension increased marginally (mean baseline of 23 ± 3 mm vs 24 ± 4 mm; mean change of 1.0 mm [95% CI: 0.2 to 1.8 mm] vs -0.3 mm [95% CI: -0.9 to 0.3 mm]; *P* = 0.02) (Table 2). Inferolateral wall thickness decreased compared with placebo (mean baseline of 12 ± 2 mm vs 11 ± 2 mm; mean change of -0.6 mm [95% CI: -0.9 to -0.3 mm] vs 0.3 mm [95% CI: 0.0 to 0.6 mm]; *P* < 0.0001) (Figure 1,

FIGURE 2 Change in Echocardiographic Parameters in a Sample Mavacamten Subject



Treatment with mavacamten led to significant improvements in LV structure and function, including SAM, mitral regurgitation, LVOT gradients, lateral e', and septal e'. LVOT = left ventricular outflow tract; other abbreviations as in Figure 1.

TABLE 2 Changes From Baseline in Resting Echocardiographic Parameters

	Mavacamten		Placebo		LS Mean Difference (95% CI), Mavacamten vs Placebo at Week 30	P Value
	n	Change (95% CI) From Baseline at Week 30	n	Change (95% CI) From Baseline at Week 30		
LVEF, %	114	-3.9 (-5.3 to -2.5)	119	-0.01 (-1.2 to 1.2)	-4.0 (-5.5 to -2.5)	<0.0001
LV end-diastolic dimension, mm	108	-1.0 (-1.5 to -0.4)	115	-0.3 (-0.9 to 0.3)	-0.7 (-1.5 to 0.0)	0.05
LV end-systolic dimension, mm	82	1.0 (0.2 to 1.8)	87	-0.3 (-0.9 to 0.3)	1.0 (0.2 to 1.9)	0.02
Interventricular septal thickness, mm	114	0.1 (-0.2 to 0.4)	120	1.4 (1.0 to 1.7)	-1.2 (-1.6 to -0.9)	<0.0001
Inferolateral wall thickness, mm	110	-0.6 (-0.9 to -0.3)	111	0.3 (0.0 to 0.6)	-0.8 (-1.2 to -0.4)	<0.0001
LVMI, g/m ²	108	-7.4 (-10.8 to -3.9)	110	8.9 (6.0 to 11.7)	-15.5 (-19.0 to -11.9)	<0.0001
LAVI, mL/m ²	115	-7.5 (-9.0 to -6.1)	123	-0.09 (-1.6 to 1.5)	-7.5 (-9.4 to -5.5)	<0.0001
Lateral e', cm/s	107	1.6 (1.2 to 1.9)	116	0.2 (-0.2 to 0.5)	1.3 (0.9 to 1.8)	<0.0001
Septal e', cm/s	113	0.7 (0.4 to 1.0)	119	-0.02 (-0.2 to 0.2)	0.7 (0.4 to 1.0)	<0.0001
E/e' lateral ratio	104	-3.8 (-4.7 to -2.8)	112	0.04 (-0.9 to 1.0)	-3.8 (-4.9 to -2.6)	<0.0001
E/e' septal ratio	111	-3.5 (-4.7 to -2.4)	117	-0.3 (-1.1 to 0.6)	-3.4 (-4.7 to -2.1)	<0.0001
Peak E-wave velocity, cm/s	111	-6.4 (-10.4 to -2.5)	122	-2.9 (-6.1 to 0.3)	-4.2 (-8.5 to 0.1)	0.06
Peak A-wave velocity, cm/s	109	-1.2 (-4.0 to 1.6)	115	0.8 (-2.3 to 4.0)	-1.9 (-5.7 to 1.8)	0.31


Values are mean (95% CI) unless otherwise indicated. No corrections for multiple testing were applied. LS = least squares; other abbreviations as in Table 1.

Table 2). Mavacamten did not significantly change [95% CI: -0.2 to 0.4 mm] vs 1.4 mm [95% CI: 1.0 to 1.7 mm]; $P < 0.0001$).
 Relationship of Baseline LVOT Gradients with Treatment Effects on Echocardiographic Parameters. A significant interaction between

TABLE 3 Linear Regression of Log2 Changes in Biomarkers and Change in pVO₂ on Echocardiographic Changes

	Mavacamten				Placebo			
	n	Intercept	Slope (95% CI)	P Value	n	Intercept	Slope (95% CI)	P Value
Log2 change in NT-proBNP, ng/L								
Resting LVOT gradient, mm Hg	114	-1.60	0.02 (0.01 to 0.03)	<0.0001	120	0.03	-0.001 (-0.006 to 0.003)	0.63
Valsalva LVOT gradient, mm Hg	114	-1.81	0.01 (0.00 to 0.02)	0.005	121	0.06	0.002 (-0.002 to 0.006)	0.35
Postexercise LVOT gradient, mm Hg	112	-1.96	0.007 (0.001 to 0.013)	0.035	118	0.03	-0.001 (-0.005 to 0.003)	0.64
LAVI, mL/m ²	112	-2.02	0.04 (0.01 to 0.07)	0.015	120	0.04	-0.002 (-0.017 to 0.013)	0.79
Lateral E/e'	101	-2.00	0.08 (0.02 to 0.13)	0.007	109	0.07	0.01 (-0.02 to 0.04)	0.39
Lateral e', cm/s	104	-2.05	-0.18 (-0.32 to -0.04)	0.011	113	0.06	0.01 (-0.06 to 0.09)	0.74
Log2 change in hs-cTnl, ng/L								
Resting LVOT gradient, mm Hg	112	-0.60	0.005 (-0.001 to 0.011)	0.12	110	-0.01	0.001 (-0.006 to 0.008)	0.83
Valsalva LVOT gradient, mm Hg	112	-0.67	0.002 (-0.003 to 0.007)	0.40	111	0.02	0.003 (-0.003 to 0.009)	0.36
Postexercise LVOT gradient, mm Hg	110	-0.79	0.000 (-0.004 to 0.004)	0.99	108	-0.06	-0.005 (-0.012 to 0.002)	0.17
LAVI, mL/m ²	111	-0.61	0.02 (0.00 to 0.05)	0.048	110	-0.01	0.005 (-0.018 to 0.028)	0.68
Lateral E/e'	100	-0.78	-0.003 (-0.040 to 0.034)	0.87	99	-0.05	-0.01 (-0.05 to 0.04)	0.76
Lateral e', cm/s	102	-0.69	-0.05 (-0.14 to 0.05)	0.32	103	-0.06	0.06 (-0.06 to 0.17)	0.32
Change in pVO ₂ , mL/kg/min								
Resting LVOT gradient, mm Hg	116	1.17	-0.01 (-0.03 to 0.01)	0.53	123	-0.13	-0.01 (-0.03 to 0.01)	0.46
Valsalva LVOT gradient, mm Hg	116	1.71	0.01 (-0.01 to 0.02)	0.46	124	-0.01	0.01 (-0.01 to 0.02)	0.41
Postexercise LVOT gradient, mm Hg	117	1.85	0.01 (-0.01 to 0.02)	0.25	122	-0.14	-0.01 (-0.03 to 0.00)	0.15
LAVI, mL/m ²	114	0.86	-0.08 (-0.15 to 0.00)	0.041	123	-0.04	0.03 (-0.03 to 0.09)	0.40
Lateral E/e'	103	1.12	-0.02 (-0.15 to 0.11)	0.73	112	-0.05	-0.06 (-0.17 to 0.06)	0.32
Lateral e', cm/s	106	0.92	0.20 (-0.12 to 0.52)	0.22	116	-0.11	-0.08 (-0.40 to 0.23)	0.59

No corrections for multiple testing were applied. n = number of patients with nonmissing change from baseline values for the pair of corresponding parameters. The results are based on a linear regression model with log2 change in NT-proBNP or log2 change in hs-cTnl or change in pVO₂ as the dependent variable and echocardiographic parameters as the independent variables. pVO₂ = peak oxygen consumption; other abbreviations as in Tables 1 and 2.

FIGURE 3 Relationship of Log₂ NT-proBNP Change and Echocardiographic Changes


Scatter plots show the linear regression of the log₂ change in NT-proBNP on changes in resting LVOT gradient (A), Valsalva LVOT gradient (B), post-exercise LVOT gradient (C), LAVI (D), lateral E/e' (E), and lateral e' (F) from baseline to week 30. NT-proBNP = N-terminal pro-B-type natriuretic peptide; other abbreviations as in Figures 1 and 2.

Continued on the next page

baseline LVOT gradients and the treatment effect on LAVI was present ($P = 0.03$) such that patients with higher baseline LVOT Valsalva gradients demonstrated greater reductions (placebo-corrected) in LAVI after adjusting for baseline LAVI and baseline LVOT Valsalva gradients. No significant interactions were seen between baseline LVOT gradients and changes in e' velocities or E/e' ratios.

RELATIONSHIP OF CHANGES TO BIOMARKERS AND EXERCISE CAPACITY. Significant associations

between reduction in serum NT-proBNP level and several echocardiographic parameters of cardiac structure and function, including LVOT gradients (rest, Valsalva, and postexercise), LAVI, E/e', and e' (Table 3, Figure 3) were seen in the mavacamten group. The reduction in resting LVOT gradient demonstrated the strongest association with reduction in NT-proBNP (mavacamten, $\beta = 0.02$, 95% CI: 0.01 to 0.03; $P < 0.0001$); this association was present in subjects with resting LVOT gradients ≥ 30 mm Hg or those with only



provokable LVOT gradients ≥ 50 mm Hg (ie, subjects with resting LVOT gradient < 50 mm Hg) (Supplemental Table 4). Also, reduction in LAVI significantly but weakly associated with reduction in serum cardiac troponin I (mavacamten, $\beta = 0.02$, 95% CI: 0.00 to 0.05; $P = 0.048$) and with increase in pV_{O_2} (mavacamten, $\beta = -0.08$, 95% CI: -0.15 to 0.00; $P = 0.041$) in patients treated with mavacamten (Table 3). No significant association was noted between troponin I or pV_{O_2} and other echocardiographic parameters (resting, Valsalva, and postexercise LVOT gradients, lateral e' , and lateral E/e') (Table 3, Supplemental Figures 1 and 2).

DISCUSSION

This analysis of EXPLORER-HCM represents the largest serial assessment of echocardiographic parameters in a prospective, double-blind, placebo-controlled study in patients with obstructive HCM. Mavacamten treatment improved several key pathophysiological features associated with obstructive HCM, thereby providing additional mechanistic insights into the improvement in exercise capacity and LVOT obstruction previously described (12). After 30 weeks of mavacamten treatment, most patients had complete resolution of mitral valve SAM, an important element in dynamic LVOT obstruction. Mavacamten also improved markers of diastolic function, including LAVI, e' , and E/e' ratio, with only a mild reduction in LV systolic function (Central Illustration). Notably, reductions in key echocardiographic parameters (LVOT gradients, LAVI, and E/e')

were associated with reductions in NT-proBNP, an important marker of cardiac wall stress with strong prognostic value (17,18).

The dynamic LVOT gradient is a key feature of obstructive HCM and is attributed to the presence of septal hypertrophy and/or mitral valve SAM. Mavacamten decreased LVOT gradients, and there was complete resolution of SAM in a majority of patients. Although similar reductions in LVOT gradients, LAVI, and E/e' were observed in those with and without complete resolution of SAM, the improvement also seen in those without complete resolution may reflect the response to partial improvement in SAM. To the extent that changes in SAM may reflect changes in mitral regurgitation, partial improvement in SAM may be sufficient to improve LVOT hemodynamics. A combination of factors may have contributed to improvement in SAM with mavacamten treatment, including reduction in hypercontractility. Early animal models attribute the reduction in contractility with mavacamten to decreased sarcomere power and force generation by decreasing myosin adenosine triphosphatase activity in a dose-dependent manner (9,19,20). The marked improvement in LVOT gradients and SAM was achieved with only a 4% mean decrease in LV ejection fraction and no significant change in heart rate, such that it appears that modifying contractility dynamics without a significant chronotropic effect with mavacamten is sufficient to relieve LVOT obstruction (12). Further studies are needed to better understand the effect of mavacamten on contractility dynamics and correlates in echocardiography.


Consistent with preclinical findings (19,20), mavacamten was associated with improved measures of diastolic function, including myocardial relaxation and compliance. Increased e' velocities, a measure of early myocardial relaxation, with mavacamten are likely the mechanical consequence of direct effects on actin-myosin cross-bridges. One potential mechanism is that reduced cross-bridge formation reduces LV stiffness and conversely improves LV compliance, resulting in lower filling pressures. In biophysical models, mavacamten has been shown to improve cross-bridge detachment, thereby improving relaxation in diastole (21). In addition, improved hemodynamics with resolution of SAM and LVOT obstruction may also improve LV filling pressure simply by relief of the obstruction. Mitral E/e' ratios, which have been shown to correlate with instantaneous LV filling pressure (22) and predict long-term outcomes in HCM patients (23-27), also showed significant improvement with mavacamten. Given that there was no significant change in E velocities, this change in E/e' appears to be driven by improvement in e' velocities or early myocardial relaxation.

In patients with obstructive HCM, elevated LA volumes, which are indicative of elevated LV filling pressures (28), may result from a combination of several possible mechanisms, including elevated LVOT gradients, mitral regurgitation secondary to SAM, and diastolic dysfunction. In this study, LAVI was mildly increased at baseline and decreased significantly in response to mavacamten. The mean reduction in LAVI of 7.5 mL/m² with only 30 weeks of therapy is consistent with the findings of a difference in LAVI reduction of 10.3 mL/m² between treatment and placebo in the cardiac magnetic resonance imaging substudy of EXPLORER-HCM (14) and reasonably comparable to the reduction in LAVI of ~10 mL/m² reported after septal reduction therapy (29,30). After accounting for baseline LAVI and baseline LVOT Valsalva gradients, those with higher baseline LVOT gradients experienced a greater decrease in LA volume, which suggests that higher LVOT gradients contribute more significantly to LA size, likely caused by a greater degree of associated mitral regurgitation. Septal reduction therapy has similarly shown that a change in LVOT gradients at peak exercise was the only echocardiographic parameter significantly associated with LAVI reverse remodeling (29). Because there was a documented improvement in SAM and mitral regurgitation and a reduction in LV filling pressures, as suggested by a decrease in E/e' , the mechanisms accounting for the reduction in LA size are likely multifactorial.

Echo Doppler-based diastolic parameters, including LAVI and E/e' , have been shown to be independent predictors of long-term outcomes, including atrial fibrillation, stroke, heart failure, cardiac transplantation, sudden cardiac death, cardiovascular mortality, and all-cause mortality in HCM patients (23-28,31-33). Notably, reductions in LVOT gradients at rest, with Valsalva, and postexercise as well as LAVI, lateral e' , and E/e' associated with reduction in serum NT-proBNP, a biomarker of cardiac wall stress that predicts morbidity and mortality in patients with HCM (17,18). Reduction in resting LVOT gradients was associated most strongly with reduction in NT-proBNP, particularly in those with resting LVOT gradients ≥ 30 mm Hg or those with only provokable gradients ≥ 50 mm Hg (ie, subjects with resting LVOT gradient < 50 mm Hg). Additionally, the association of improvement in LAVI and E/e' with improvement in NT-proBNP supports the effect of mavacamten in reducing LV filling pressure with reduction in LVOT gradients. Patients with non-obstructive HCM treated with mavacamten in the MAVERICK-HCM (Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy) trial also exhibited significant reductions in NT-proBNP, which suggests that mavacamten favorably impacts LV filling pressures by additional mechanisms apart from the observed improvement in LVOT gradients and SAM in obstructive HCM patients; this may be attributed to mavacamten's additional impact on diastolic function (34). Finally, reduction in LAVI was the only echocardiographic parameter change that associated with improvement in functional capacity, suggesting that LA volume change in response to therapy may be more predictive of improvement in functional status compared with other echocardiographic measures, including LVOT gradient reduction. This is supported by data that have shown that increased LA volume is inversely associated with treadmill exercise capacity in HCM and further supports LAVI as a marker of HCM pathophysiology (33).

Although there are known limitations to 2-dimensional measurement-derived LV mass calculations by echocardiography (35), particularly in the setting of asymmetric hypertrophy, our data suggest a statistically significant decline in wall thickness and LVMI with mavacamten vs placebo. These data are concordant with the recently published cardiac magnetic resonance imaging substudy of EXPLORER-HCM, wherein mean LVMI decreased by 15.8 g/m² and maximum wall thickness decreased by 2.4 mm in the mavacamten group compared with placebo (14).

CENTRAL ILLUSTRATION Mechanism of Action of Mavacamten and Observed Changes



Hegde, S.M. et al. J Am Coll Cardiol. 2021;78(25):2518-2532.

Reduction of actin-myosin cross-bridges with 30 weeks of mavacamten led to improvements in several echocardiographic parameters. e' = early diastolic mitral annular velocity; E/e' = ratio between early mitral inflow velocity and mitral annular early diastolic velocity; HCM = hypertrophic cardiomyopathy; LAVI = left atrial volume index; LVEF = left ventricular ejection fraction; LVOT = left ventricular outflow tract; SAM = systolic anterior motion.

These changes in wall thickness/mass are also in keeping with other small observational cohorts after septal reduction therapy in which reduction in lateral wall thickness accompanies reduction in septal wall thickness as soon as 6 months postprocedure; this suggests that relief of LVOT obstruction and afterload reduction may contribute to reduction in LV wall thickness (29,30,36). Alternatively, reduction in wall thickness may be a direct result of fewer actin-myosin cross-bridges and/or reflect the associated mild decrease in contractility and LV function observed during the 30 weeks of study. The MAVA-LTE (Mavacamten Long-Term Extension study; NCT03723655) and other longitudinal studies will better clarify the impact of mavacamten therapy on cardiac hypertrophy.

The improvements in LV diastolic function, cardiac morphology, and biomarkers observed with mavacamten have not been reported in relation to contemporary pharmacologic therapies for symptomatic obstructive HCM, such as β -blockers, non-dihydropyridine calcium-channel blockers, and disopyramide (37,38). In contrast, improvement in LA volumes, LV wall thickness, SAM, and NT-proBNP have been reported with successful septal reduction therapy, such as septal ablation and septal myectomy (29,30,36,39). Mavacamten appears to improve the underlying pathophysiology in HCM and may provide similar benefit without the need for invasive therapy and procedural risk. Further investigation of the effect of mavacamten on septal reduction therapy eligibility and the number of septal reduction therapy procedures performed in obstructive HCM patients is currently underway in the VALOR-HCM (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy; NCT04349072).

STUDY LIMITATIONS. The EXPLORER-HCM study design excluded patients with mild symptoms (New York Heart Association functional class I), those on disopyramide therapy, and those with LV ejection fraction <55%, and there was limited participation of ethnic minorities and younger patients (age <50 years). Hence, our findings may not be generalizable to these subpopulations of obstructive HCM patients in the community. A small proportion of patients had a history of septal reduction therapy and atrial fibrillation, which may have affected measures of diastolic function. SAM and mitral regurgitation were only semiquantitatively assessed as present or absent in this study; the highly eccentric nature of the mitral regurgitation in obstructive HCM does not lend itself to accurate or reliable quantification. The protocol also

precluded the use of ultrasound-enhancing agents to avoid confounding effects on interpretations of adverse events. Last, EXPLORER-HCM was a relatively short duration study of 30 weeks. The ongoing long-term extension study (MAVA-LTE) will reveal whether these early benefits with mavacamten treatment persist beyond 30 weeks.

CONCLUSIONS

In this analysis of EXPLORER-HCM, mavacamten was associated with favorable changes in cardiac structure and function through 30 weeks of therapy, including improvement in echocardiographic markers of LV filling pressures (LAVI and E/e'), LVOT gradients, and SAM. Additionally, improvements in LVOT gradients, LAVI, and E/e' were associated with reductions in NT-proBNP.

ACKNOWLEDGMENTS The authors thank the patients who participated in the EXPLORER-HCM study and their families, as well as the study co-investigators, research nurses, and coordinators at each of the clinical sites. The authors also thank the cardiac sonographers at each site and the entire Brigham and Women's Hospital Cardiovascular Imaging Core Laboratory team. Editorial support was provided by Kim Fuller, PhD, of Cello Health Communications/SciFluent Communications, and was supported by MyoKardia, Inc, a wholly owned subsidiary of Bristol Myers Squibb.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

Study funding was provided by MyoKardia, Inc, Brisbane, CA, a wholly owned subsidiary of Bristol Myers Squibb. Dr Hegde serves on the faculty of the Cardiovascular Imaging Core Laboratory at Brigham and Women's Hospital; and her institution has received payments for her consulting work from MyoKardia. Dr Lester's institution has received payments for his consulting work for MyoKardia. Dr Solomon is Director of the Cardiovascular Imaging Core Laboratory at Brigham and Women's Hospital; has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, Lone Star Heart, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, NeuroTronik, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, and Theracos; and has consulted for Abbott, Action Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GlaxoSmithKline, Ironwood, Lilly, Merck, MyoKardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, AOBiome, Janssen, Cardiac Dimensions, Tenaya, Sanofi Pasteur, DiNAQOR, Trembeau, CellProthera, Moderna, and American Regent. Dr Michels has received personal fees and payments as a consultant from MyoKardia. Dr Elliott has received payments as a consultant from MyoKardia, Pfizer, AstraZeneca, and Sanofi Genzyme; and has received speaker fees from Sanofi Genzyme. Dr Zemanek has received speaking honoraria from Abbott and Bayer. Dr Zwas has received personal fees from MyoKardia. Dr Jacoby has received personal fees from MyoKardia. Dr Wang has received grants and payments as a

consultant from MyoKardia; and has received personal fees from Cytokinetics. Dr Ho has received payments as a consultant from MyoKardia, Tenaya, Novartis, and Ambry Genetics. Drs Li and Sehnert are employees of and have stocks or stock options in MyoKardia. Dr Olivetto has received grants from MyoKardia, Sanofi Genzyme, Shire, and Bayer; has received personal fees from Sanofi Genzyme, Shire, Amicus, and Bayer; and has received payments as a consultant from MyoKardia and Cytokinetics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Sheila M. Hegde, Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA. E-mail: shegde@bwh.harvard.edu.

PERSPECTIVES

COMPETENCY IN PATIENT CARE AND PROCEDURAL

OUTCOMES: In patients with obstructive HCM, treatment with mavacamten, a cardiac myosin inhibitor, reduces SAM of the mitral valve and LVOT gradient and improves echocardiographic markers of LV diastolic function and exercise capacity.

TRANSLATIONAL OUTLOOK: Additional studies are needed to understand the mechanism by which mavacamten improves diastolic function and better characterize its long-term therapeutic effects in patients with obstructive HCM.

REFERENCES

- Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. *Circ Res*. 2017;121:749-770.
- Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2020;76(25):e159-e240.
- Maron MS, Olivetto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. *N Engl J Med*. 2003;348:295-303.
- Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe). *Circulation*. 2018;138:1387-1398.
- Elliott PM, Anastakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J*. 2014;35:2733-2779.
- Sherrid MV. Drug therapy for hypertrophic cardiomyopathy: physiology and practice. *Curr Cardiol Rev*. 2016;12:52-65.
- Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivetto I. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. *Eur J Heart Fail*. 2016;18:1106-1118.
- Grillo MP, Erve JCL, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. *Xenobiotica*. 2019;49:718-733.
- Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. *Science*. 2016;351:617-621.
- Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. *J Biol Chem*. 2017;292:16571-16577.
- Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. *Ann Intern Med*. 2019;170:741-748.
- Olivetto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2020;396:759-769.
- Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2021;397:2467-2475.
- Saberi S, Cardim N, Yamani MH, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM CMR substudy analysis. *Circulation*. 2020;143:606-608.
- Ho CY, Olivetto I, Jacoby D, et al. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic cardiomyopathy. *Circ Heart Fail*. 2020;13(6):e006853. <https://doi.org/10.1161/CIRCHEARTFAILURE.120.006853>
- Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1-39e14.
- Geske JB, McKie PM, Ommen SR, Sorajja P. B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2013;61:2456-2460.
- Coats CJ, Gallagher MJ, Foley M, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. *Eur Heart J*. 2013;34:2529-2537.
- del Rio CL, Ueyama Y, Baker DC, et al. Abstract 20593: In vivo cardiac effects of mavacamten (MYK-461): evidence for negative inotropy and improved compliance (abstr). *Circulation*. 2018;136(Suppl 1):A20593.
- del Rio CL, Yadav A, Huang N, et al. Abstract 13204: Acute effects of a small-molecule direct myosin-attenuator (MYK-581) in a mini-pig genetic model of non-obstructed hypertrophic cardiomyopathy: in vivo evidence for contractile regulation with improved compliance and functional reserve (abstr). *Circulation*. 2018;138:A13204.
- Awinda PO, Watanabe M, Bishaw YM, et al. Mavacamten Decreases Maximal Force and Ca(2+)-sensitivity in the N47K-Myosin Regulatory Light Chain Mouse Model of Hypertrophic Cardiomyopathy. *Am J Physiol Heart Circ Physiol*. 2021;320(2):H881-H890. <https://doi.org/10.1152/ajpheart.00345.2020>
- Nagueh SF. Non-invasive assessment of left ventricular filling pressure. *Eur J Heart Fail*. 2018;20:38-48.
- Debonnaire P, Joyce E, Hiemstra Y, et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2017;10(2):e004052. <https://doi.org/10.1161/CIRCEP.116.004052>
- Costabel JP, Galve E, Terricabras M, et al. E/e' ratio and left atrial area are predictors of atrial fibrillation in patients with hypertrophic cardiomyopathy. *Echocardiography*. 2018;35:935-940.
- Efthimiadis GK, Giannakoulas G, Parcharidou DG, et al. Clinical significance of tissue Doppler imaging in patients with hypertrophic cardiomyopathy. *Circ J*. 2007;71:897-903.
- Badran HM, Soltan G, Almeleigi R, Faheem N, Yacoub MH. Prognostic significance of left ventricular end diastolic pressure using E/E' in patients with hypertrophic cardiomyopathy. *Echocardiography*. 2019;36:2167-2175.

27. Lu DY, Hailelessie B, Ventoulis I, et al. E/e' ratio and outcome prediction in hypertrophic cardiomyopathy: the influence of outflow tract obstruction. *Eur Heart J Cardiovasc Imaging*. 2018;19:101-107.
28. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29:277-314.
29. Finocchiaro G, Haddad F, Kobayashi Y, et al. Impact of Septal Reduction on Left Atrial Size and Diastole in Hypertrophic Cardiomyopathy. *Echocardiography*. 2016;33:686-694.
30. Moravsky G, Bruchal-Garbicz B, Jamorski M, et al. Myocardial mechanical remodeling after septal myectomy for severe obstructive hypertrophic cardiomyopathy. *J Am Soc Echocardiogr*. 2013;26:893-900.
31. Pinamonti B, Merlo M, Nangah R, et al. The progression of left ventricular systolic and diastolic dysfunctions in hypertrophic cardiomyopathy: clinical and prognostic significance. *J Cardiovasc Med (Hagerstown)*. 2010;11:669-677.
32. Nistri S, Olivetto I, Betocchi S, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). *Am J Cardiol*. 2006;98:960-965.
33. Yang WJ, Shim CY, Kim YJ, et al. Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. *J Am Soc Echocardiogr*. 2009;22:1338-1343.
34. Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2020;75:2649-2660.
35. Corona-Villalobos CP, Sorensen LL, Pozios I, et al. Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography. *Int J Cardiovasc Imaging*. 2016;32:945-954.
36. Dabrowski M, Kukula K, Klopotoski M, et al. Reduction of left ventricular mass, left atrial size, and N-terminal pro-B-type natriuretic peptide level following alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. *Kardiol Pol*. 2019;77:181-189.
37. Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2005;45:1251-1258.
38. Sherrid MV, Shetty A, Winson G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil. *Circ Heart Fail*. 2013;6:694-702.
39. Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. *Circulation*. 1999;99:344-347.

KEY WORDS diastolic function, hypertrophic cardiomyopathy, mavacamten, N-terminal pro-B-type natriuretic peptide

APPENDIX For supplemental tables and figures, please see the online version of this paper.